CoChat

Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery

Pardridge, William M · 2015 · Expert Opinion on Therapeutic Targets

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The blood-brain barrier (BBB) limits the uptake of most drugs by brain, and the traditional approach to the BBB problem is the use of medicinal chemistry to increase drug lipid solubility, and increase lipid-mediated transport across the BBB. This review advocates a new model to CNS drug discovery of BBB-penetrating small molecules, whereby drug candidates are screened for carrier-mediated transport (CMT) across the BBB. AREAS COVERED: CMT systems are expressed by genes within the Solute Carrier (SLC) Transporter Gene Family, which now totals > 400 transporter genes. Emphasis is placed on reconciliation of the substrate transporter profile (STP) of BBB transport in vivo with the STP of the cloned SLC transporter in vitro. This reconciliation is crucial to the identification, from sometimes a large number of candidates, of the respective SLC transporter that is responsible for BBB transport in vivo for a given class of nutrients. EXPERT OPINION: Dual track screening of a small molecule library for drugs that have the dual properties of affinity for a neural cell drug receptor target, and affinity for a BBB CMT transporter target, can lead to a revolution in how small molecule drugs are identified in CNS drug discovery programs.

Overview

Integrity signals

Registry

Crossref · 10.1517/14728222.2015.1042364

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 72 references

Research works printed but not linked: 7

  1. Cornford EM, 1992, Cancer Res, 52, 138
  2. Takasato Y, 1984, Am J Physiol, 247, H484
  3. Dwyer KJ, 1993, Endocrinology, 132, 558, 10.1210/endo.132.2.8093876 · doi:10.1210/endo.132.2.8093876 · Paper page
  4. Gerhart DZ, 1997, Am J Physiol, 273, E207
  5. Berne RM, 1983, Fed Proc, 42, 3136
  6. Mejia AA, 1991, J Nucl Med, 32, 699
  7. Inoue T, 1999, J Nucl Med, 40, 399

Cited by

See all 167

Metadata

Authors
Pardridge, W. M.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Pardridge, William M
Venue
Expert Opinion on Therapeutic Targets
Published
2015-05-02
Volume
19
Issue
8
Pages
1059-1072
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2046677279
Cited by
159
References
72
Citations by year
2026: 8 · 2025: 20 · 2024: 17 · 2023: 11 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 9 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 3
FWCI
1.58
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
blood-brain barrier, carrier-mediated transport, solute carrier transporters, CNS drug discovery, small molecule drug candidates, transporter affinity, drug penetration into brain
MeSH terms
Animals, Biological Transport, Blood-Brain Barrier, Brain, Pharmaceutical Preparations, Humans, Lipids, Solubility, Drug Delivery Systems, Membrane Transport Proteins, Small Molecule Libraries, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. https://app.cochat.ai/papers/10.1517/14728222.2015.1042364
The paper
Pardridge, W. M. (2015). Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2015.1042364

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.